Cargando…
A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic de...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980589/ https://www.ncbi.nlm.nih.gov/pubmed/29281161 http://dx.doi.org/10.1111/hex.12661 |
_version_ | 1783327902927945728 |
---|---|
author | Harmsen, Marline G. Steenbeek, Miranda P. Hoogerbrugge, Nicoline van Doorn, Helena C. Gaarenstroom, Katja N. Vos, M. Caroline Massuger, Leon F.A.G. de Hullu, Joanne A. Hermens, Rosella P.M.G. |
author_facet | Harmsen, Marline G. Steenbeek, Miranda P. Hoogerbrugge, Nicoline van Doorn, Helena C. Gaarenstroom, Katja N. Vos, M. Caroline Massuger, Leon F.A.G. de Hullu, Joanne A. Hermens, Rosella P.M.G. |
author_sort | Harmsen, Marline G. |
collection | PubMed |
description | BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic development of a patient decision aid in an iterative process of prototype development, alpha testing by patients and clinicians and revisions using International Patient Decision Aid Standards (IPDAS) quality criteria. Information was based on the available literature and current guidelines. A multidisciplinary steering group supervised the process. SETTING AND PARTICIPANTS: Pre‐menopausal BRCA1/2 mutation carriers choosing between RRSO and salpingectomy with delayed oophorectomy in Family Cancer Clinics in the Netherlands. MAIN OUTCOME MEASURES: IPDAS quality criteria, relevance, usability, clarity. RESULTS: The patient decision aid underwent four rounds of alpha testing and revisions. Finally, two paper decision aids were developed: one for BRCA1 and one for BRCA2. They both contained a general introduction, three chapters and a step‐by‐step plan containing a personal value clarification worksheet. During alpha testing, risk communication and information about premature menopause and hormone therapy were the most revised items. The patient decision aids fulfil 37 of 43 (86%) IPDAS criteria for content and development process. DISCUSSION AND CONCLUSIONS: Both BRCA1/2 mutation carriers and professionals are willing to use or offer the developed patient decision aids for risk‐reducing surgery. The patient decision aids have been found clear, balanced and comprehensible. Future testing among patients facing the decision should point out its effectiveness in improving decision making. |
format | Online Article Text |
id | pubmed-5980589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59805892018-06-07 A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing Harmsen, Marline G. Steenbeek, Miranda P. Hoogerbrugge, Nicoline van Doorn, Helena C. Gaarenstroom, Katja N. Vos, M. Caroline Massuger, Leon F.A.G. de Hullu, Joanne A. Hermens, Rosella P.M.G. Health Expect Original Research Papers BACKGROUND: BRCA1/2 mutation carriers’ choice between risk‐reducing salpingo‐oophorectomy (RRSO) and salpingectomy with delayed oophorectomy is very complex. Aim was to develop a patient decision aid that combines evidence with patient preferences to facilitate decision making. DESIGN: Systematic development of a patient decision aid in an iterative process of prototype development, alpha testing by patients and clinicians and revisions using International Patient Decision Aid Standards (IPDAS) quality criteria. Information was based on the available literature and current guidelines. A multidisciplinary steering group supervised the process. SETTING AND PARTICIPANTS: Pre‐menopausal BRCA1/2 mutation carriers choosing between RRSO and salpingectomy with delayed oophorectomy in Family Cancer Clinics in the Netherlands. MAIN OUTCOME MEASURES: IPDAS quality criteria, relevance, usability, clarity. RESULTS: The patient decision aid underwent four rounds of alpha testing and revisions. Finally, two paper decision aids were developed: one for BRCA1 and one for BRCA2. They both contained a general introduction, three chapters and a step‐by‐step plan containing a personal value clarification worksheet. During alpha testing, risk communication and information about premature menopause and hormone therapy were the most revised items. The patient decision aids fulfil 37 of 43 (86%) IPDAS criteria for content and development process. DISCUSSION AND CONCLUSIONS: Both BRCA1/2 mutation carriers and professionals are willing to use or offer the developed patient decision aids for risk‐reducing surgery. The patient decision aids have been found clear, balanced and comprehensible. Future testing among patients facing the decision should point out its effectiveness in improving decision making. John Wiley and Sons Inc. 2017-12-27 2018-06 /pmc/articles/PMC5980589/ /pubmed/29281161 http://dx.doi.org/10.1111/hex.12661 Text en © 2017 The Authors Health Expectations published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Papers Harmsen, Marline G. Steenbeek, Miranda P. Hoogerbrugge, Nicoline van Doorn, Helena C. Gaarenstroom, Katja N. Vos, M. Caroline Massuger, Leon F.A.G. de Hullu, Joanne A. Hermens, Rosella P.M.G. A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title | A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title_full | A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title_fullStr | A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title_full_unstemmed | A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title_short | A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing |
title_sort | patient decision aid for risk‐reducing surgery in premenopausal brca1/2 mutation carriers: development process and pilot testing |
topic | Original Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980589/ https://www.ncbi.nlm.nih.gov/pubmed/29281161 http://dx.doi.org/10.1111/hex.12661 |
work_keys_str_mv | AT harmsenmarlineg apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT steenbeekmirandap apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT hoogerbruggenicoline apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT vandoornhelenac apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT gaarenstroomkatjan apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT vosmcaroline apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT massugerleonfag apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT dehullujoannea apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT hermensrosellapmg apatientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT harmsenmarlineg patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT steenbeekmirandap patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT hoogerbruggenicoline patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT vandoornhelenac patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT gaarenstroomkatjan patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT vosmcaroline patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT massugerleonfag patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT dehullujoannea patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting AT hermensrosellapmg patientdecisionaidforriskreducingsurgeryinpremenopausalbrca12mutationcarriersdevelopmentprocessandpilottesting |